Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Translate in Chinese

PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors

Author(s): Julia Alejandra Pezuk, Elvis Terci Valera, María Sol Brassesco.

Graphical Abstract:


Over the years, polo-like kinase 1 (PLK1) has garnered great interest as a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response in eukaryotic cells. In this review, we summarize the functions of PLK1 during cell cycle progression, its roles in human pediatric cancer and its value as a prognostic factor. Furthermore, we introduce the advances in pharmacological inhibition and the newly chemotherapeutic development of small-molecules to target PLK1 in cancer treatment. Finally, clinical trials with PLK1 inhibitors are briefly reviewed.

Keywords: Chemotherapy, inhibitors, pediatric tumors, PLK1, radiotherapy, treatment.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2016
Page: [1661 - 1672]
Pages: 12
DOI: 10.2174/1389450116666150825120235
Price: $58